{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-033365","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2023-09-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.965367+00:00","generated_at":"2026-06-10T10:51:33.518647+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vivos Therapeutics receives Nasdaq delisting notice; plans to appeal","bullets":["Nasdaq determined company failed to meet $1.00 minimum bid price as of Sept 20, 2023; delisting proceedings begun.","Also failed to meet $2.5M minimum stockholders' equity requirement as of June 30, 2023.","Company will timely appeal and request a hearing by Sept 28, 2023; hearing stays delisting pending decision.","Reverse stock split proposal on Sept 22 annual meeting agenda to regain bid price compliance.","No assurance hearing panel will grant continued listing; delisting risk remains."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-033365","json":"https://secwatch.observer/filing/0001493152-23-033365.json","markdown":"https://secwatch.observer/filing/0001493152-23-033365.md","text":"https://secwatch.observer/filing/0001493152-23-033365.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223033365/0001493152-23-033365-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223033365/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T10:51:33.518647+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d5e565fc17556fd632f747f33593b69975c14a5","claim":"Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"August 17, 2023, the Company received a staff deficiency notice from Nasdaq indicating that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1), which requires that a listed company’s stockholders’ equity be at least $2,500,000 (the “Minimum Stockholders’ Equity Requirement”). On September 21, 2023, the Company received a written notice (the “Notice”) from the Nasdaq staff confirming the staff’s determination that the Company had, a","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223033365/0001493152-23-033365-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"6c74a7d25ff459372319feb3592afa9a64bcba7d","claim":"Vivos Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"September 21, 2023, the Company received a written notice (the “Notice”) from the Nasdaq staff confirming the staff’s determination that the Company had, as of the date of the Notice, failed to meet the Minimum Bid Requirement and that Nasdaq would commence delisting proceedings against the Company. The Company may appeal the Nasdaq staff’s determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, no later than 4:00 pm Eastern Time on September 28, 2023. The Company plans to timely file such an appeal and request a hearing (the “Hearing”) before a Nasdaq Heari","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223033365/0001493152-23-033365-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}